Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update

European Journal of Pharmacology

Volumn 791, Issue , 2016, Pages 8-24

  Bhattacharjee, Niloy ^a   Barma, Sujata ^a   Konwar, Nandita ^b   Dewanjee, Saikat ^a   Manna, Prasenjit ^b  

^a JADAVPUR UNIVERSITY   (India)

^b CSIR NEIST   (India)

Author keywords

Diabetic nephropathy; Hyperglycemia; Oxidative stress responsive signaling cascade; Pharmacotherapeitics

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; ALISKIREN; ALPHA TOCOPHEROL; ANTHRAQUINONE; ASCORBIC ACID; AST 120; BENFOTIAMINE; BETA GLUCAN; CHEMOKINE; CYTOKINE; FENOFIBRATE; HEXOSAMINE; JANUS KINASE; JANUS KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MANIDIPINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; POLYOL; PROTEIN KINASE C; RAPAMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; SMAD PROTEIN; STAT PROTEIN; TELMISARTAN; THIOCTIC ACID; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

APOPTOSIS; DIABETIC NEPHROPATHY; DRUG APPROVAL; DRUG TARGETING; ENZYME ACTIVATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84984611800     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.08.022     Document Type: Review

References (245)

1. Abe, H., Recent progress in understanding the molecular pathogenesis of diabetic nephropathy. Rinsho Byori 59 (2011), 179–186.
2. Adhikary, L., Chow, F., Nikolic-Paterson, D.J., Stambe, C., Dowling, J., Atkins, R.C., Tesch, G.H., Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47 (2004), 1210–1222.
3. Adler, S., Striker, L.J., Striker, G.E., Perkinson, D.T., Hibbert, J., Couser, W.G., Studies of progressive glomerular sclerosis in the rat. Am. J. Pathol. 123 (1986), 553–562.
4. Adler, S.G., Schwartz, S., Williams, M.E., Arauz-Pacheco, C., Bolton, W.K., Lee, T., Li, D., Neff, T.B., Urquilla, P.R., Sewell, K.L., Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5 (2010), 1420–1428.
5. Alkhalaf, A., Klooster, A., van Oeveren, W., Achenbach, U., Kleefstra, N., Slingerland, R.J., Mijnhout, G.S., Bilo, H.J., Gans, R.O., Navis, G.J., Bakker, S.J., A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33 (2010), 1598–1601.
6. Altenhofer, S., Kleikers, P.W., Radermacher, K.A., Scheurer, P., Rob Hermans, J.J., Schiffers, P., Ho, H., Wingler, K., Schmidt, H.H., The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol. Life Sci. 69 (2012), 2327–2343.
7. Alter, M.L., Ott, I.M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Krause-Relle, K., Raila, J., Henze, A., Klein, T., Hocher, B., DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press. Res. 36 (2012), 119–130.
8. Amiri, F., Shaw, S., Wang, X., Tang, J., Waller, J.L., Eaton, D.C., Marrero, M.B., Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int. 61 (2002), 1605–1616.
9. Asaba, K., Tojo, A., Onozato, M.L., Goto, A., Fujita, T., Double-edged action of SOD mimetic in diabetic nephropathy. J. Cardiovasc. Pharm. 49 (2007), 13–19.
10. Asanuma, K., Shirato, I., Ishidoh, K., Kominami, E., Tomino, Y., Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int. 62 (2002), 822–831.
11. Avruch, J., Lin, Y., Long, X., Murthy, S., Ortiz-Vega, S., Recent advances in the regulation of the TOR pathway by insulin and nutrients. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005), 67–72.
12. Barutta, F., Corbelli, A., Mastrocola, R., Gambino, R., Di Marzo, V., Pinach, S., Rastaldi, M.P., Perin, P.C., Gruden, G., Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 59 (2010), 1046–1054.
13. Berthier, C.C., Zhang, H., Schin, M., Henger, A., Nelson, R.G., Yee, B., Boucherot, A., Neusser, M.A., Cohen, C.D., Carter-Su, C., Argetsinger, L.S., Rastaldi, M.P., Brosius, F.C., Kretzler, M., Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58 (2009), 469–477.
14. Block, K., Gorin, Y., Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 12 (2012), 627–637.
15. Blouza, S., Dakhli, S., Abid, H., Aissaoui, M., Ardhaoui, I., Ben Abdallah, N., Ben Brahim, S., Ben Ghorbel, I., Ben Salem, N., Beji, S., Chamakhi, S., Derbel, A., Derouiche, F., Djait, F., Doghri, T., Fourti, Y., Gharbi, F., Jellouli, K., Jellazi, N., Kamoun, K., Khedher, A., Letaief, A., Limam, R., Mekaouer, A., Miledi, R., Nagati, K., Naouar, M., Sellem, S., Tarzi, H., Turki, S., Zidi, B., Achour, A., Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J. Nephrol. 23 (2010), 415–424.
16. Bogoyevitch, M.A., Boehm, I., Oakley, A., Ketterman, A.J., Barr, R.K., Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 1697 (2004), 89–101.
17. Bolton, W.K., Cattran, D.C., Williams, M.E., Adler, S.G., Appel, G.B., Cartwright, K., Foiles, P.G., Freedman, B.I., Raskin, P., Ratner, R.E., Spinowitz, B.S., Whittier, F.C., Wuerth, J.P., Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24 (2004), 32–40.
18. Bonventre, J.V., Can we target tubular damage to prevent renal function decline in diabetes?. Semin. Nephrol. 32 (2012), 452–462.
19. Boucherot, A.H.A., C.C, Schin, M.L., Burke, K., Bayer, I., HRM, Schmid, Schlondorff, D., Brosius, F., Kretzler, M., Jak/Stat activation in diabetic nephropathy in humans but not mice: transcriptional analysis. J. Am. Soc. Nephrol., 17, 2006, 60A.
20. Bran, G.M., Goessler, U.R., Schardt, C., Hormann, K., Riedel, F., Sadick, H., Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars. Int. J. Mol. Med 25 (2010), 915–921.
21. Brownlee, M., Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 43 (1994), 836–841.
22. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001), 813–820.
23. Brownlee, M., Cerami, A., Vlassara, H., Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New Engl. J. Med. 318 (1988), 1315–1321.
24. Cai, W., He, J.C., Zhu, L., Chen, X., Zheng, F., Striker, G.E., Vlassara, H., Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am. J. Pathol. 173 (2008), 327–336.
25. Cai, W., He, J.C., Zhu, L., Lu, C., Vlassara, H., Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc. Natl. Acad. Sci. USA 103 (2006), 13801–13806.
26. Cavalieri, L., Cremonesi, G., Metabolic effects of manidipine. Am. J. Cardiovasc. Drugs : drugs, devices, other interv. 9 (2009), 163–176.
27. Chander, P.N., Gealekman, O., Brodsky, S.V., Elitok, S., Tojo, A., Crabtree, M., Gross, S.S., Goligorsky, M.S., Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J. Am. Soc. Nephrol. 15 (2004), 2391–2403.
28. Chen, C.A., Hwang, J.C., Guh, J.Y., Tsai, J.C., Chen, H.C., TGF-beta1 and integrin synergistically facilitate the differentiation of rat podocytes by increasing alpha-smooth muscle actin expression. Transl. Res. 148 (2006), 134–141.
29. Chen, H.Y., Huang, X.R., Wang, W., Li, J.H., Heuchel, R.L., Chung, A.C., Lan, H.Y., The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60 (2011), 590–601.
30. Chen, J.K., Chen, J., Thomas, G., Kozma, S.C., Harris, R.C., S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am. J. Physiol. Ren. Physiol. 297 (2009), F585–F593.
31. Chen, L.L., Zhang, J.Y., Wang, B.P., Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vasc. Pharm. 44 (2006), 309–315.
32. Chen, Y.J., Quilley, J., Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J. Pharm. Exp. Ther. 324 (2008), 658–663.
33. Chen, Z., Zhang, D., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D.R., The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J. Biol. Chem. 287 (2012), 17016–17028.
34. Cheng, D.W., Jiang, Y., Shalev, A., Kowluru, R., Crook, E.D., Singh, L.P., An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells. Arch. Physiol. Biochem. 112 (2006), 189–218.
35. Cheng, G., Cao, Z., Xu, X., van Meir, E.G., Lambeth, J.D., Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269 (2001), 131–140.
36. Chuang, P.Y., Yu, Q., Fang, W., Uribarri, J., He, J.C., Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 72 (2007), 965–976.
37. Coughlan, M.T., Forbes, J.M., Cooper, M.E., Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int.(Suppl.), 2007, S54–S60.
38. Darling, N.J., Cook, S.J., The role of MAPK signalling pathways in the response to endoplasmic reticulum stress. Biochim. Biophys. Acta 1843 (2014), 2150–2163.
39. de Borst, M.H., Prakash, J., Melenhorst, W.B., van den Heuvel, M.C., Kok, R.J., Navis, G., van Goor, H., Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. J. Pathol. 213 (2007), 219–228.
40. de Borst, M.H., Prakash, J., Sandovici, M., Klok, P.A., Hamming, I., Kok, R.J., Navis, G., van Goor, H., c-Jun NH2-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. J. Pharmacol. Exp. Ther. 331 (2009), 896–905.
41. Derynck, R., Zhang, Y.E., Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003), 577–584.
42. Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999), 649–688.
43. Deutsch, D.G., Goligorsky, M.S., Schmid, P.C., Krebsbach, R.J., Schmid, H.H., Das, S.K., Dey, S.K., Arreaza, G., Thorup, C., Stefano, G., Moore, L.C., Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100 (1997), 1538–1546.
44. Devaraj, S., Tobias, P., Jialal, I., Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 55 (2011), 441–445.
45. Dvornik, E., Simard-Duquesne, N., Krami, M., Sestanj, K., Gabbay, K.H., Kinoshita, J.H., Varma, S.D., Merola, L.O., Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science 182 (1973), 1146–1148.
46. Elmarakby, A.A., Sullivan, J.C., Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc. Ther. 30 (2012), 49–59.
47. English, J.M., Cobb, M.H., Pharmacological inhibitors of MAPK pathways. Trends Pharmacol. Sci. 23 (2002), 40–45.
48. Farvid, M.S., Homayouni, F., Amiri, Z., Adelmanesh, F., Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation. Diabetes Res Clin. Pr. 93 (2011), 86–94.
49. Farvid, M.S., Jalali, M., Siassi, F., Hosseini, M., Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 28 (2005), 2458–2464.
50. Fingar, D.C., Blenis, J., Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 (2004), 3151–3171.
51. Fioretto, P., Mauer, M., Histopathology of diabetic nephropathy. Semin. Nephrol. 27 (2007), 195–207.
52. Flanc, R.S., Ma, F.Y., Tesch, G.H., Han, Y., Atkins, R.C., Bennett, B.L., Friedman, G.C., Fan, J.H., Nikolic-Paterson, D.J., A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int. 72 (2007), 698–708.
53. Fujita, H., Omori, S., Ishikura, K., Hida, M., Awazu, M., ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am. J. Physiol. Ren. Physiol. 286 (2004), F120–F126.
54. Gal, N., Kolusheva, S., Kedei, N., Telek, A., Naeem, T.A., Lewin, N.E., Lim, L., Mannan, P., Garfield, S.H., El Kazzouli, S., Sigano, D.M., Marquez, V.E., Blumberg, P.M., Jelinek, R., N-methyl-substituted fluorescent DAG-indololactone isomers exhibit dramatic differences in membrane interactions and biological activity. Chembiochem 12 (2011), 2331–2340.
55. Gava, E., Samad-Zadeh, A., Zimpelmann, J., Bahramifarid, N., Kitten, G.T., Santos, R.A., Touyz, R.M., Burns, K.D., Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol., Dial. Transplant., 24, 2009 1766-1773 Official publication of the European Dialysis and Transplant Association - European Renal Association.
56. Gill, P.S., Wilcox, C.S., NADPH oxidases in the kidney. Antioxid. Redox Signal. 8 (2006), 1597–1607.
57. Godel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mor, A., Lindenmeyer, M.T., Rastaldi, M.P., Hartleben, G., Wiech, T., Fornoni, A., Nelson, R.G., Kretzler, M., Wanke, R., Pavenstadt, H., Kerjaschki, D., Cohen, C.D., Hall, M.N., Ruegg, M.A., Inoki, K., Walz, G., Huber, T.B., Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J. Clin. Investig. 121 (2011), 2197–2209.
58. Gorin, Y., Block, K., Hernandez, J., Bhandari, B., Wagner, B., Barnes, J.L., Abboud, H.E., Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J. Biol. Chem. 280 (2005), 39616–39626.
59. Gorin, Y., Ricono, J.M., Kim, N.H., Bhandari, B., Choudhury, G.G., Abboud, H.E., Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am. J. Physiol. Ren. Physiol. 285 (2003), F219–F229.
60. Guan, Y., Breyer, M.D., Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 60 (2001), 14–30.
61. Guh, J.Y., Huang, J.S., Chen, H.C., Hung, W.C., Lai, Y.H., Chuang, L.Y., Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am. J. Kidney Dis. 38 (2001), 1096–1104.
62. Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E., Shaw, R.J., AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30 (2008), 214–226.
63. Ha, H., Yu, M.R., Choi, Y.J., Lee, H.B., Activation of protein kinase c-delta and c-epsilon by oxidative stress in early diabetic rat kidney. Am. J. Kidney Dis. 38 (2001), S204–S207.
64. Haneda, M., Araki, S., Togawa, M., Sugimoto, T., Isono, M., Kikkawa, R., Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46 (1997), 847–853.
65. Harrington, L.S., Findlay, G.M., Lamb, R.F., Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 30 (2005), 35–42.
66. Hay, N., Sonenberg, N., Upstream and downstream of mTOR. Genes Dev. 18 (2004), 1926–1945.
67. Hayashi, K., Ozawa, Y., Fujiwara, K., Wakino, S., Kumagai, H., Saruta, T., Role of actions of calcium antagonists on efferent arterioles–with special references to glomerular hypertension. Am. J. Nephrol. 23 (2003), 229–244.
68. Hayashida, T., Schnaper, H.W., High ambient glucose enhances sensitivity to TGF-beta1 via extracellular signal–regulated kinase and protein kinase Cdelta activities in human mesangial cells. J. Am. Soc. Nephrol. 15 (2004), 2032–2041.
69. Holz, M.K., Ballif, B.A., Gygi, S.P., Blenis, J., mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123 (2005), 569–580.
70. Hu, Z., Ren, L., Wang, C., Liu, B., Song, G., Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats. Kidney Blood Press. Res. 36 (2012), 85–97.
71. Huang, J.S., Guh, J.Y., Hung, W.C., Yang, M.L., Lai, Y.H., Chen, H.C., Chuang, L.Y., Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem. J. 342:Pt 1 (1999), 231–238.
72. Huber, T.B., Walz, G., Kuehn, E.W., mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int. 79 (2011), 502–511.
73. Igarashi, M., Wakasaki, H., Takahara, N., Ishii, H., Jiang, Z.Y., Yamauchi, T., Kuboki, K., Meier, M., Rhodes, C.J., King, G.L., Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J. Clin. Investig. 103 (1999), 185–195.
74. Iimura, O., Shimamoto, K., Masuda, A., Higashiura, K., Miyazaki, Y., Hirata, A., Fukuoka, M., Murakami, H., Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J. Diabetes Complicat. 9 (1995), 215–219.
75. Ijaz, A., Tejada, T., Catanuto, P., Xia, X., Elliot, S.J., Lenz, O., Jauregui, A., Saenz, M.O., Molano, R.D., Pileggi, A., Ricordi, C., Fornoni, A., Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int. 75 (2009), 381–388.
76. Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S.M., Ikenoue, T., Ruegg, M.A., Hall, M.N., Kwiatkowski, D.J., Rastaldi, M.P., Huber, T.B., Kretzler, M., Holzman, L.B., Wiggins, R.C., Guan, K.L., mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Investig. 121 (2011), 2181–2196.
77. Irita, J., Okura, T., Jotoku, M., Nagao, T., Enomoto, D., Kurata, M., Desilva, V.R., Miyoshi, K., Matsui, Y., Uede, T., Denhardt, D.T., Rittiling, S.R., Higaki, J., Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am. J. Physiol. Ren. Physiol. 301 (2011), F833–F844.
78. Ishibashi, Y., Matsui, T., Takeuchi, M., Yamagishi, S., Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun. 391 (2010), 1405–1408.
79. Ishibashi, Y., Yamagishi, S., Matsui, T., Ohta, K., Tanoue, R., Takeuchi, M., Ueda, S., Nakamura, K., Okuda, S., Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism 61 (2012), 1067–1072.
80. Isono, M., Cruz, M.C., Chen, S., Hong, S.W., Ziyadeh, F.N., Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. J. Am. Soc. Nephrol. 11 (2000), 2222–2230.
81. Ito, Y., Aten, J., Bende, R.J., Oemar, B.S., Rabelink, T.J., Weening, J.J., Goldschmeding, R., Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53 (1998), 853–861.
82. Izuhara, Y., Sada, T., Yanagisawa, H., Koike, H., Ohtomo, S., Dan, T., Ito, S., Nangaku, M., van Ypersele de Strihou, C., Miyata, T., A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb. Vasc. Biol. 28 (2008), 1767–1773.
83. Izuhara, Y., Takahashi, S., Nangaku, M., Takizawa, S., Ishida, H., Kurokawa, K., van Ypersele de Strihou, C., Hirayama, N., Miyata, T., Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb. Vasc. Biol. 28 (2008), 672–677.
84. Izuhara, Y., Yamaoka, N., Kodama, H., Dan, T., Takizawa, S., Hirayama, N., Meguro, K., van Ypersele de Strihou, C., Miyata, T., A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J. Cereb. Blood Flow Metab. 30 (2010), 904–912.
85. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., Su, B., SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006), 125–137.
86. Janiak, P., Poirier, B., Bidouard, J.P., Cadrouvele, C., Pierre, F., Gouraud, L., Barbosa, I., Dedio, J., Maffrand, J.P., Le Fur, G., O'Connor, S., Herbert, J.M., Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 72 (2007), 1345–1357.
87. Jankun, J., Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: a case report. Exp. Ther. Med. 4 (2012), 661–664.
88. Juan, Y.S., Chuang, S.M., Long, C.Y., Lin, R.J., Liu, K.M., Wu, W.J., Huang, C.H., Protein kinase C inhibitor prevents renal apoptotic and fibrotic changes in response to partial ureteric obstruction. BJU Int. 110 (2012), 283–292.
89. Jung, D.H., Kim, Y.S., Kim, N.H., Lee, J., Jang, D.S., Kim, J.S., Extract of Cassiae Semen and its major compound inhibit S100b-induced TGF-beta1 and fibronectin expression in mouse glomerular mesangial cells. Eur. J. Pharm. 641 (2010), 7–14.
90. Jung, D.S., Li, J.J., Kwak, S.J., Lee, S.H., Park, J., Song, Y.S., Yoo, T.H., Han, S.H., Lee, J.E., Kim, D.K., Moon, S.J., Kim, Y.S., Han, D.S., Kang, S.W., FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells. Am. J. Physiol. Ren. Physiol. 295 (2008), F595–F604.
91. Jung, K.Y., Chen, K., Kretzler, M., Wu, C., TGF-beta1 regulates the PINCH-1-integrin-linked kinase-alpha-parvin complex in glomerular cells. J. Am. Soc. Nephrol. 18 (2007), 66–73.
92. Kage-Nakadai, E., Uehara, T., Mitani, S., H+/myo-inositol transporter genes, hmit-1.1 and hmit-1.2, have roles in the osmoprotective response in Caenorhabditis elegans. Biochem. Biophys. Res Commun. 410 (2011), 471–477.
93. Kang, Y.S., Li, Y., Dai, C., Kiss, L.P., Wu, C., Liu, Y., Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int. 78 (2010), 363–373.
94. Kennedy, L., Solano, M.P., Meneghini, L., Lo, M., Cohen, M.P., Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. Am. J. Nephrol. 31 (2010), 110–116.
95. Kiel, C., Serrano, L., Challenges ahead in signal transduction: MAPK as an example. Curr. Opin. Biotechnol. 23 (2012), 305–314.
96. Kim, J.H., Kim, B.K., Moon, K.C., Hong, H.K., Lee, H.S., Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 64 (2003), 1715–1721.
97. Kimoto, K., Nakatsuka, K., Matsuo, N., Yoshioka, H., p38 MAPK mediates the expression of type I collagen induced by TGF-beta 2 in human retinal pigment epithelial cells ARPE-19. Invest. Ophthalmol. Vis. Sci. 45 (2004), 2431–2437.
98. Ko, B., Cooke, L.L., Hoover, R.S., Parathyroid hormone (PTH) regulates the sodium chloride cotransporter via Ras guanyl releasing protein 1 (Ras-GRP1) and extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) pathway. Transl. Res. 158 (2011), 282–289.
99. Ko, G.J., Kang, Y.S., Han, S.Y., Lee, M.H., Song, H.K., Han, K.H., Kim, H.K., Han, J.Y., Cha, D.R., Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant. 23 (2008), 2750–2760.
100. Koli, K., Myllarniemi, M., Keski-Oja, J., Kinnula, V.L., Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox Signal. 10 (2008), 333–342.
101. Koli, K., Saharinen, J., Hyytiainen, M., Penttinen, C., Keski-Oja, J., Latency, activation, and binding proteins of TGF-beta. Microsc. Res. Tech. 52 (2001), 354–362.
102. Kolm-Litty, V., Sauer, U., Nerlich, A., Lehmann, R., Schleicher, E.D., High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101 (1998), 160–169.
103. Kumar, B., Gupta, S.K., Srinivasan, B.P., Nag, T.C., Srivastava, S., Saxena, R., Hesperetin ameliorates hyperglycemia induced retinal vasculopathy via anti-angiogenic effects in experimental diabetic rats. Vasc. Pharm. 57 (2012), 201–207.
104. Kuo, C.W., Shen, C.J., Tung, Y.T., Chen, H.L., Chen, Y.H., Chang, W.H., Cheng, K.C., Yang, S.H., Chen, C.M., Extracellular superoxide dismutase ameliorates streptozotocin-induced rat diabetic nephropathy via inhibiting the ROS/ERK1/2 signaling. Life Sci. 135 (2015), 77–86.
105. Kyriakis, J.M., Avruch, J., Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001), 807–869.
106. Lakshmanan, A.P., Thandavarayan, R.A., Watanabe, K., Sari, F.R., Meilei, H., Giridharan, V.V., Sukumaran, V., Soetikno, V., Arumugam, S., Suzuki, K., Kodama, M., Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. Mol. Cell. Endocrinol. 348 (2012), 104–111.
107. Lakshmanan, A.P., Watanabe, K., Thandavarayan, R.A., Sari, F.R., Harima, M., Giridharan, V.V., Soetikno, V., Kodama, M., Aizawa, Y., Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-gamma agonist action. Free Radic. Res. 45 (2011), 575–584.
108. Lee, H.S., Mechanisms and consequences of TGF-ss overexpression by podocytes in progressive podocyte disease. Cell Tissue Res. 347 (2012), 129–140.
109. Lee, H.S., Song, C.Y., Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press. Res 33 (2010), 24–29.
110. Li, X., Hu, J., Zhang, Q., Sun, X., Li, S., Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta 1 and VEGF. Br. J. Pharmacol. 157 (2009), 994–1003.
111. Li, Y., Kang, Y.S., Dai, C., Kiss, L.P., Wen, X., Liu, Y., Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am. J. Pathol. 172 (2008), 299–308.
112. Lim, A.K., Ma, F.Y., Nikolic-Paterson, D.J., Ozols, E., Young, M.J., Bennett, B.L., Friedman, G.C., Tesch, G.H., Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats. Am. J. Nephrol. 34 (2011), 337–346.
113. Lim, A.K., Nikolic-Paterson, D.J., Ma, F.Y., Ozols, E., Thomas, M.C., Flavell, R.A., Davis, R.J., Tesch, G.H., Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetologia 52 (2009), 347–358.
114. Lin, M., Yiu, W.H., Wu, H.J., Chan, L.Y., Leung, J.C., Au, W.S., Chan, K.W., Lai, K.N., Tang, S.C., Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol. 23 (2012), 86–102.
115. Lindsley, J.E., Rutter, J., Nutrient sensing and metabolic decisions. Comp. Biochem. Physiol. B: Biochem. Mol. Biol. 139 (2004), 543–559.
116. Liu, J.P., Feng, L., Zhu, M.M., Wang, R.S., Zhang, M.H., Hu, S.Y., Jia, X.B., Wu, J.J., The in vitro protective effects of curcumin and demethoxycurcumin in Curcuma longa extract on advanced glycation end products-induced mesangial cell apoptosis and oxidative stress. Planta Med. 78 (2012), 1757–1760.
117. Liu, Y.W., Zhu, X., Zhang, L., Lu, Q., Wang, J.Y., Zhang, F., Guo, H., Yin, J.L., Yin, X.X., Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Eur. J. Pharm. 721 (2013), 355–364.
118. Lloberas, N., Cruzado, J.M., Franquesa, M., Herrero-Fresneda, I., Torras, J., Alperovich, G., Rama, I., Vidal, A., Grinyo, J.M., Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol. 17 (2006), 1395–1404.
119. Lu, T.C., Wang, Z.H., Feng, X., Chuang, P.Y., Fang, W., Shen, Y., Levy, D.E., Xiong, H., Chen, N., He, J.C., Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int. 76 (2009), 63–71.
120. Ma, F.Y., Flanc, R.S., Tesch, G.H., Han, Y., Atkins, R.C., Bennett, B.L., Friedman, G.C., Fan, J.H., Nikolic-Paterson, D.J., A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J. Am. Soc. Nephrol. 18 (2007), 472–484.
121. Ma, F.Y., Liu, J., Nikolic-Paterson, D.J., The role of stress-activated protein kinase signaling in renal pathophysiology. Braz. J. Med. Biol. Res. 42 (2009), 29–37.
122. Manna, P., Kalita, J., Beneficial role of vitamin K supplementation on insulin sensitivity, glucose metabolism, and the reduced risk of type 2 diabetes: a review. Nutrition, 32, 2016 732-739 (Burbank, Los Angeles County, Calif.).
123. Mariappan, M.M., Senthil, D., Natarajan, K.S., Choudhury, G.G., Kasinath, B.S., Phospholipase Cgamma-Erk Axis in vascular endothelial growth factor-induced eukaryotic initiation factor 4E phosphorylation and protein synthesis in renal epithelial cells. J. Biol. Chem. 280 (2005), 28402–28411.
124. McClain, D.A., Crook, E.D., Hexosamines and insulin resistance. Diabetes 45 (1996), 1003–1009.
125. McKeage, K., Scott, L.J., Manidipine: a review of its use in the management of hypertension. Drugs 64 (2004), 1923–1940.
126. Medicherla, S., Wadsworth, S., Cullen, B., Silcock, D., Ma, J.Y., Mangadu, R., Kerr, I., Chakravarty, S., Luedtke, G.L., Dugar, S., Protter, A.A., Higgins, L.S., p38 MAPK inhibition reduces diabetes-induced impairment of wound healing. Diabetes, Metab. Syndr. Obes. : Targets Ther. 2 (2009), 91–100.
127. Mehta, J.L., The role of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein, in atherosclerosis. Can. J. Cardiol. 20:Suppl B (2004), 32B–36B.
128. Meier, M., Menne, J., Park, J.K., Holtz, M., Gueler, F., Kirsch, T., Schiffer, M., Mengel, M., Lindschau, C., Leitges, M., Haller, H., Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J. Am. Soc. Nephrol. 18 (2007), 1190–1198.
129. Menne, J., Park, J.K., Boehne, M., Elger, M., Lindschau, C., Kirsch, T., Meier, M., Gueler, F., Fiebeler, A., Bahlmann, F.H., Leitges, M., Haller, H., Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 53 (2004), 2101–2109.
130. Meyers, M.J., Arhancet, G.B., Hockerman, S.L., Chen, X., Long, S.A., Mahoney, M.W., Rico, J.R., Garland, D.J., Blinn, J.R., Collins, J.T., Yang, S., Huang, H.C., McGee, K.F., Wendling, J.M., Dietz, J.D., Payne, M.A., Homer, B.L., Heron, M.I., Reitz, D.B., Hu, X., Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J. Med. Chem. 53 (2010), 5979–6002.
131. Mihailović, M., Arambašić, J., Uskoković, A., Dinić, S., Grdović, N., Marković, J., Bauder, J., Poznanović, G., Vidaković, M., β-Glucan administration to diabetic rats alleviates oxidative stress by lowering hyperglycaemia, decreasing non-enzymatic glycation and protein O-GlcNAcylation. J. Funct. Foods 5 (2013), 1226–1234.
132. Mishra, A., Bhatti, R., Singh, A., Singh Ishar, M.P., Ameliorative effect of the cinnamon oil from Cinnamomum zeylanicum upon early stage diabetic nephropathy. Planta Med. 76 (2010), 412–417.
133. Miyazono, K., ten Dijke, P., Heldin, C.H., TGF-beta signaling by Smad proteins. Adv. Immunol. 75 (2000), 115–157.
134. Moghaddam, H.K., Baluchnejadmojarad, T., Roghani, M., Khaksari, M., Norouzi, P., Ahooie, M., Mahboobi, F., Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol. Neurobiol. 49 (2014), 820–826.
135. Moon, J.A., Kim, H.T., Cho, I.S., Sheen, Y.Y., Kim, D.K., IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 70 (2006), 1234–1243.
136. Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., Okamura, H., Koga, M., Fukuchi, M., Hada, T., Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52 (2003), 605–608.
137. Morrison, D.K., Cutler, R.E., The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 9 (1997), 174–179.
138. Mott, J.D., Khalifah, R.G., Nagase, H., Shield, C.F. 3rd, Hudson, J.K., Hudson, B.G., Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 52 (1997), 1302–1312.
139. Mukhopadhyay, P., Pan, H., Rajesh, M., Batkai, S., Patel, V., Harvey-White, J., Mukhopadhyay, B., Hasko, G., Gao, B., Mackie, K., Pacher, P., CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br. J. Pharmacol. 160 (2010), 657–668.
140. Mukhopadhyay, P., Rajesh, M., Pan, H., Patel, V., Mukhopadhyay, B., Batkai, S., Gao, B., Hasko, G., Pacher, P., Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic. Biol. Med. 48 (2010), 457–467.
141. Murakoshi, M., Tanimoto, M., Gohda, T., Hagiwara, S., Ohara, I., Toyoda, H., Ishikawa, Y., Horikoshi, S., Tomino, Y., Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetes Res. Clin. Pract. 83 (2009), 183–189.
142. Muthenna, P., Raghu, G., Kumar, P.A., Surekha, M.V., Reddy, G.B., Effect of cinnamon and its procyanidin-B2 enriched fraction on diabetic nephropathy in rats. Chem. Biol. Interact. 222C (2014), 68–76.
143. Nagao, T., Okura, T., Irita, J., Jotoku, M., Enomoto, D., Desilva, V.R., Miyoshi, K., Kurata, M., Matsui, Y., Uede, T., Higaki, J., Osteopontin plays a critical role in interstitial fibrosis but not glomerular sclerosis in diabetic nephropathy. Nephron Extra 2 (2012), 87–103.
144. Nakano, S., Kobayashi, N., Yoshida, K., Ohno, T., Matsuoka, H., Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens. Res. 28 (2005), 925–936.
145. Ohshiro, Y., Ma, R.C., Yasuda, Y., Hiraoka-Yamamoto, J., Clermont, A.C., Isshiki, K., Yagi, K., Arikawa, E., Kern, T.S., King, G.L., Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 55 (2006), 3112–3120.
146. Ojima, A., Ishibashi, Y., Matsui, T., Maeda, S., Nishino, Y., Takeuchi, M., Fukami, K., Yamagishi, S., Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am. J. Pathol. 182 (2013), 132–141.
147. Okamoto, M., Fuchigami, M., Suzuki, T., Watanabe, N., A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models. Biol. Pharm. Bull. 35 (2012), 2069–2074.
148. Onozato, M.L., Tojo, A., Kobayashi, N., Goto, A., Matsuoka, H., Fujita, T., Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol. Dial. Transplant. 22 (2007), 1314–1322.
149. Ortiz, A., Egido, J., Is there a role for specific anti-TNF strategies in glomerular diseases?. Nephrol. Dial. Transplant. 10 (1995), 309–311.
150. Osaki, T., Azuma, K., Kurozumi, S., Takamori, Y., Tsuka, T., Imagawa, T., Okamoto, Y., Minami, S., Metabolomic analyses of blood plasma after oral administration of D-glucosamine hydrochloride to dogs. Mar. Drugs 10 (2012), 1873–1882.
151. Owada, A., Suda, S., Hata, T., Effect of long-term administration of prostaglandin I(2) in incipient diabetic nephropathy. Nephron 92 (2002), 788–796.
152. Packham, D.K., Alves, T.P., Dwyer, J.P., Atkins, R., de Zeeuw, D., Cooper, M., Shahinfar, S., Lewis, J.B., Lambers Heerspink, H.J., Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am. J. Kidney Dis. 59 (2012), 75–83.
153. Pan, Y., Zhang, X., Wang, Y., Cai, L., Ren, L., Tang, L., Wang, J., Zhao, Y., Wang, Y., Liu, Q., Li, X., Liang, G., Targeting JNK by a new curcumin analog to inhibit NF-kB-mediated expression of cell adhesion molecules attenuates renal macrophage infiltration and injury in diabetic mice. PloS One, 8, 2013, e79084.
154. Park, C.W., Kim, H.W., Ko, S.H., Chung, H.W., Lim, S.W., Yang, C.W., Chang, Y.S., Sugawara, A., Guan, Y., Breyer, M.D., Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55 (2006), 885–893.
155. Park, S.K., Dahmer, M.K., Quasney, M.W., MAPK and JAK-STAT signaling pathways are involved in the oxidative stress-induced decrease in expression of surfactant protein genes. Cell Physiol. Biochem. 30 (2012), 334–346.
156. Parving, H.H., Diabetic nephropathy: prevention and treatment. Kidney Int. 60 (2001), 2041–2055.
157. Pawelczyk, T., Grden, M., Rzepko, R., Sakowicz, M., Szutowicz, A., Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am. J. Pathol. 167 (2005), 315–325.
158. Petersen, M., Thorikay, M., Deckers, M., van Dinther, M., Grygielko, E.T., Gellibert, F., de Gouville, A.C., Huet, S., ten Dijke, P., Laping, N.J., Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73 (2008), 705–715.
159. Piek, E., Heldin, C.H., Ten Dijke, P., Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 13 (1999), 2105–2124.
160. Porras, A., Zuluaga, S., Black, E., Valladares, A., Alvarez, A.M., Ambrosino, C., Benito, M., Nebreda, A.R., P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol. Biol. Cell 15 (2004), 922–933.
161. Puddu, A., Sanguineti, R., Durante, A., Nicolo, M., Viviani, G.L., Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol. Vis. 18 (2012), 2509–2517.
162. Pugliese, G., Pricci, F., Iacobini, C., Leto, G., Amadio, L., Barsotti, P., Frigeri, L., Hsu, D.K., Vlassara, H., Liu, F.T., Di Mario, U., Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. : Off. Publ. Fed. Am. Soc. Exp. Biol. 15 (2001), 2471–2479.
163. Ramana, K.V., Aldose reductase: new insights for an old enzyme. Biomol. Concepts 2 (2011), 103–114.
164. Rane, M.J., Song, Y., Jin, S., Barati, M.T., Wu, R., Kausar, H., Tan, Y., Wang, Y., Zhou, G., Klein, J.B., Li, X., Cai, L., Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 298 (2010), F49–F61.
165. Renno, W.M., Abdeen, S., Alkhalaf, M., Asfar, S., Effect of green tea on kidney tubules of diabetic rats. Br. J. Nutr. 100 (2008), 652–659.
166. Rossing, P., Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr. Diab Rep. 6 (2006), 479–483.
167. Roux, P.P., Blenis, J., ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol. Biol. Rev. 68 (2004), 320–344.
168. Sai Varsha, M.K., Raman, T., Manikandan, R., Dhanasekaran, G., Hypoglycemic action of vitamin K1 protects against early-onset diabetic nephropathy in streptozotocin-induced rats. Nutrition 31 (2015), 1284–1292.
169. Sakai, N., Wada, T., Furuichi, K., Iwata, Y., Yoshimoto, K., Kitagawa, K., Kokubo, S., Kobayashi, M., Hara, A., Yamahana, J., Okumura, T., Takasawa, K., Takeda, S., Yoshimura, M., Kida, H., Yokoyama, H., Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am. J. Kidney Dis. 45 (2005), 54–65.
170. Sansone, P., Bromberg, J., Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 30 (2012), 1005–1014.
171. Sataranatarajan, K., Mariappan, M.M., Lee, M.J., Feliers, D., Choudhury, G.G., Barnes, J.L., Kasinath, B.S., Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am. J. Pathol. 171 (2007), 1733–1742.
172. Satirapoj, B., Nast, C.C., Adler, S.G., Novel insights into the relationship between glomerular pathology and progressive kidney disease. Adv. Chronic Kidney Dis. 19 (2012), 93–100.
173. Schiffer, M., Bitzer, M., Roberts, I.S., Kopp, J.B., ten Dijke, P., Mundel, P., Bottinger, E.P., Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Invest 108 (2001), 807–816.
174. Sedeek, M., Gutsol, A., Montezano, A.C., Burger, D., Nguyen Dinh Cat, A., Kennedy, C.R., Burns, K.D., Cooper, M.E., Jandeleit-Dahm, K., Page, P., Szyndralewiez, C., Heitz, F., Hebert, R.L., Touyz, R.M., Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin. Sci. (Lond.) 124 (2013), 191–202.
175. Sedeek, M., Hebert, R.L., Kennedy, C.R., Burns, K.D., Touyz, R.M., Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr. Opin. Nephrol. Hypertens. 18 (2009), 122–127.
176. Sehgal, S.N., Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35 (2003), 7s–14s.
177. Seldon, M.P., Silva, G., Pejanovic, N., Larsen, R., Gregoire, I.P., Filipe, J., Anrather, J., Soares, M.P., Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of NF-kappaB RelA phosphorylation at serine 276. J. Immunol. 179 (2007), 7840–7851.
178. Sen, U., Rodriguez, W.E., Tyagi, N., Kumar, M., Kundu, S., Tyagi, S.C., Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am. J. Physiol. Endocrinol. Metab. 295 (2008), E1205–E1212.
179. Shahbazian, D., Roux, P.P., Mieulet, V., Cohen, M.S., Raught, B., Taunton, J., Hershey, J.W., Blenis, J., Pende, M., Sonenberg, N., The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 25 (2006), 2781–2791.
180. Shankland, S.J., Pippin, J., Pichler, R.H., Gordon, K.L., Friedman, S., Gold, L.I., Johnson, R.J., Couser, W.G., Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 50 (1996), 116–124.
181. Shi, Y.H., Zhao, S., Wang, C., Li, Y., Duan, H.J., Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions. Acta Pharm. Sin. 28 (2007), 1938–1946.
182. Shibata, S., Nagase, M., Yoshida, S., Kawachi, H., Fujita, T., Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49 (2007), 355–364.
183. Singh, B.N., Shankar, S., Srivastava, R.K., Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharm. 82 (2011), 1807–1821.
184. Singh, V.P., Baker, K.M., Kumar, R., Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am. J. Physiol. Heart Circ. Physiol. 294 (2008), H1675–H1684.
185. Smith, E.M., Finn, S.G., Tee, A.R., Browne, G.J., Proud, C.G., The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280 (2005), 18717–18727.
186. Song, J., Eyster, K.M., Kost, C.K. Jr., Kjellsen, B., Martin, D.S., Involvement of protein kinase C-CPI-17 in androgen modulation of angiotensin II-renal vasoconstriction. Cardiovasc Res 85 (2010), 614–621.
187. Steinberg, S.F., Structural basis of protein kinase C isoform function. Physiol. Rev. 88 (2008), 1341–1378.
188. Stielow, C., Catar, R.A., Muller, G., Wingler, K., Scheurer, P., Schmidt, H.H., Morawietz, H., Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys. Res Commun. 344 (2006), 200–205.
189. Streeter, J., Thiel, W., Brieger, K., Miller, F.J. Jr., Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. Cardiovasc Ther. 31 (2013), 125–137.
190. Su, Z., Zimpelmann, J., Burns, K.D., Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 69 (2006), 2212–2218.
191. Sullivan, T.J., Dairaghi, D.J., Krasinski, A., Miao, Z., Wang, Y., Zhao, B.N., Baumgart, T., Berahovich, R., Ertl, L.S., Pennell, A., Seitz, L., Miao, S., Ungashe, S., Wei, Z., Johnson, D., Boring, L., Tsou, C.L., Charo, I.F., Bekker, P., Schall, T.J., Jaen, J.C., Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. J. Pharm. Exp. Ther., 2012.
192. Susztak, K., Raff, A.C., Schiffer, M., Bottinger, E.P., Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55 (2006), 225–233.
193. Suzuki, D., Miyata, T., Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern Med 38 (1999), 309–314.
194. Suzuki, D., Miyata, T., Saotome, N., Horie, K., Inagi, R., Yasuda, Y., Uchida, K., Izuhara, Y., Yagame, M., Sakai, H., Kurokawa, K., Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J. Am. Soc. Nephrol. 10 (1999), 822–832.
195. Suzuki, H., Uchida, K., Nitta, K., Nihei, H., Role of mitogen-activated protein kinase in the regulation of transforming growth factor-beta-induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin. Exp. Nephrol. 8 (2004), 188–195.
196. Tadege, M., Mysore, K.S., Tnt1 retrotransposon tagging of STF in Medicago truncatula reveals tight coordination of metabolic, hormonal and developmental signals during leaf morphogenesis. Mob. Genet Elem. 1 (2011), 301–303.
197. Takaishi, H., Taniguchi, T., Takahashi, A., Ishikawa, Y., Yokoyama, M., High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys. Res Commun. 305 (2003), 122–128.
198. Takenaka, K., Yamagishi, S., Matsui, T., Nakamura, K., Imaizumi, T., Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr. neurovascular Res. 3 (2006), 73–77.
199. Tampe, D., Zeisberg, M., Potential approaches to reverse or repair renal fibrosis. Nat. Rev. Nephrol. 10 (2014), 226–237.
200. Tervaert, T.W., Mooyaart, A.L., Amann, K., Cohen, A.H., Cook, H.T., Drachenberg, C.B., Ferrario, F., Fogo, A.B., Haas, M., de Heer, E., Joh, K., Noel, L.H., Radhakrishnan, J., Seshan, S.V., Bajema, I.M., Bruijn, J.A., Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 21 (2010), 556–563.
201. Thallas-Bonke, V., Jha, J.C., Gray, S.P., Barit, D., Haller, H., Schmidt, H.H., Coughlan, M.T., Cooper, M.E., Forbes, J.M., Jandeleit-Dahm, K.A., Nox-4 deletion reduces oxidative stress and injury by PKC-alpha-associated mechanisms in diabetic nephropathy. Physiol. Rep., 2, 2014.
202. Thallas-Bonke, V., Thorpe, S.R., Coughlan, M.T., Fukami, K., Yap, F.Y., Sourris, K.C., Penfold, S.A., Bach, L.A., Cooper, M.E., Forbes, J.M., Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57 (2008), 460–469.
203. Thomas, M.C., Forbes, J.M., Cooper, M.E., Advanced glycation end products and diabetic nephropathy. Am. J. Ther. 12 (2005), 562–572.
204. Tian, L., Li, C., Qi, J., Fu, P., Yu, X., Li, X., Cai, L., Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. Am. J. Physiol. Endocrinol. Metab. 295 (2008), E1234–E1242.
205. Tikoo, K., Lodea, S., Karpe, P.A., Kumar, S., Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy. Biochem Biophys. Res Commun. 450 (2014), 1581–1586.
206. Tournier, C., Hess, P., Yang, D.D., Xu, J., Turner, T.K., Nimnual, A., Bar-Sagi, D., Jones, S.N., Flavell, R.A., Davis, R.J., Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Sci. (New Y., N. Y. ) 288 (2000), 870–874.
207. Tracz, M.J., Juncos, J.P., Grande, J.P., Croatt, A.J., Ackerman, A.W., Katusic, Z.S., Nath, K.A., Induction of heme oxygenase-1 is a beneficial response in a murine model of venous thrombosis. Am. J. Pathol. 173 (2008), 1882–1890.
208. Tuttle, K.R., Bakris, G.L., Toto, R.D., McGill, J.B., Hu, K., Anderson, P.W., The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28 (2005), 2686–2690.
209. Uribarri, J., Woodruff, S., Goodman, S., Cai, W., Chen, X., Pyzik, R., Yong, A., Striker, G.E., Vlassara, H., Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet. Assoc. 110 (2010), 911–916 e912.
210. Utsugi, M., Dobashi, K., Ishizuka, T., Masubuchi, K., Shimizu, Y., Nakazawa, T., Mori, M., C-Jun-NH2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-beta1 in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 28 (2003), 754–761.
211. Vitzthum, H., Weiss, B., Bachleitner, W., Kramer, B.K., Kurtz, A., Gene expression of adenosine receptors along the nephron. Kidney Int 65 (2004), 1180–1190.
212. Vogt, L., Chiurchiu, C., Chadha-Boreham, H., Danaietash, P., Dingemanse, J., Hadjadj, S., Krum, H., Navis, G., Neuhart, E., Parvanova, A.I., Ruggenenti, P., Woittiez, A.J., Zimlichman, R., Remuzzi, G., de Zeeuw, D., Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension 55 (2010), 1206–1209.
213. Voziyan, P.A., Hudson, B.G., Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann. N Y Acad. Sci. 1043 (2005), 807–816.
214. Wahab, N.A., Schaefer, L., Weston, B.S., Yiannikouris, O., Wright, A., Babelova, A., Schaefer, R., Mason, R.M., Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48 (2005), 2650–2660.
215. Wang, D., Dai, C., Li, Y., Liu, Y., Canonical Wnt/beta-catenin signaling mediates transforming growth factor-beta1-driven podocyte injury and proteinuria. Kidney Int 80 (2011), 1159–1169.
216. Wang, L., Matsushita, K., Araki, I., Takeda, M., Inhibition of c-Jun N-terminal kinase ameliorates apoptosis induced by hydrogen peroxide in the kidney tubule epithelial cells (NRK-52E). Nephron 91 (2002), 142–147.
217. Wang, W., Wang, Y., Long, J., Wang, J., Haudek, S.B., Overbeek, P., Chang, B.H., Schumacker, P.T., Danesh, F.R., Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab. 15 (2012), 186–200.
218. Wang, X., Shaw, S., Amiri, F., Eaton, D.C., Marrero, M.B., Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 51 (2002), 3505–3509.
219. Weiss, R., Niecestro, R., Raz, I., The role of sulodexide in the treatment of diabetic nephropathy. Drugs 67 (2007), 2681–2696.
220. Wenzel, R.R., Littke, T., Kuranoff, S., Jurgens, C., Bruck, H., Ritz, E., Philipp, T., Mitchell, A., Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20 (2009), 655–664.
221. Wilkinson, M.G., Millar, J.B., Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J. 14 (2000), 2147–2157.
222. Wilmer, W.A., Dixon, C.L., Hebert, C., Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int 60 (2001), 858–871.
223. Wittmann, S., Daniel, C., Stief, A., Vogelbacher, R., Amann, K., Hugo, C., Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 87 (2009), 1290–1299.
224. Wolf, G., New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur. J. Clin. Invest 34 (2004), 785–796.
225. Wolf, G., Reinking, R., Zahner, G., Stahl, R.A., Shankland, S.J., Erk 1,2 phosphorylates p27(Kip1): Functional evidence for a role in high glucose-induced hypertrophy of mesangial cells. Diabetologia 46 (2003), 1090–1099.
226. Wolf, G., Schanze, A., Stahl, R.A., Shankland, S.J., Amann, K., p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int 68 (2005), 1583–1589.
227. Wolf, G., Schroeder, R., Thaiss, F., Ziyadeh, F.N., Helmchen, U., Stahl, R.A., Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 53 (1998), 869–879.
228. Wu, D., Peng, F., Zhang, B., Ingram, A.J., Kelly, D.J., Gilbert, R.E., Gao, B., Krepinsky, J.C., PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. J. Am. Soc. Nephrol. 20 (2009), 554–566.
229. Wullschleger, S., Loewith, R., Hall, M.N., TOR signaling in growth and metabolism. Cell 124 (2006), 471–484.
230. Xia, L., Wang, H., Goldberg, H.J., Munk, S., Fantus, I.G., Whiteside, C.I., Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am. J. Physiol. Ren. Physiol. 290 (2006), F345–F356.
231. Yamagishi, S., Maeda, S., Matsui, T., Ueda, S., Fukami, K., Okuda, S., Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys. Acta 1820 (2012), 663–671.
232. Yamagishi, S., Nakamura, K., Matsui, T., Inoue, H., Takeuchi, M., Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Med Hypotheses 69 (2007), 666–668.
233. Yang, Y., Wang, J., Qin, L., Shou, Z., Zhao, J., Wang, H., Chen, Y., Chen, J., Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am. J. Nephrol. 27 (2007), 495–502.
234. Yao, L., Wang, J., Mao, Y., Zhu, H., Deng, A., Zhu, Z., Different expressions of protein kinase C-alpha, beta I and beta II in glomeruli of diabetic nephropathy patients. J. Huazhong Univ. Sci. Technol. Med Sci. 26 (2006), 651–653.
235. Yong, R., Chen, X.M., Shen, S., Vijayaraj, S., Ma, Q., Pollock, C.A., Saad, S., Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling. PLoS One, 8, 2013, e73428.
236. Yoo, K.H., Thornhill, B.A., Forbes, M.S., Coleman, C.M., Marcinko, E.S., Liaw, L., Chevalier, R.L., Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int 70 (2006), 1735–1741.
237. Yu, Y., Kang, P.F., Li, H.H., Zhang, G.J., Wang, F.F., Ye, H.W., Gao, Q., [Effects of activation of ALDH2 by ethanol on the expression of JNK in kidney of diabetic rats]. Zhongguo ying yong sheng li xue za zhi=Zhongguo yingyong shenglixue zazhi= Chin. J. Appl. Physiol. 30 (2014), 270–273.
238. Zhang, H., Jia, Y., Cooper, J.J., Hale, T., Zhang, Z., Elbein, S.C., Common variants in glutamine: fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels. J. Clin. Endocrinol. Metab. 89 (2004), 748–755.
239. Zhang, S., Zhang, Y., Wei, X., Zhen, J., Wang, Z., Li, M., Miao, W., Ding, H., Du, P., Zhang, W., He, M., Yi, F., Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys. Acta 1802 (2010), 1078–1086.
240. Zhang, S.L., Tang, S.S., Chen, X., Filep, J.G., Ingelfinger, J.R., Chan, J.S., High levels of glucose stimulate angiotensinogen gene expression via the P38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology 141 (2000), 4637–4646.
241. Zheng, J., Inoguchi, T., Sasaki, S., Maeda, Y., McCarty, M.F., Fujii, M., Ikeda, N., Kobayashi, K., Sonoda, N., Takayanagi, R., Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304 (2013), R110–R120.
242. Zheng, J.M., Zhu, J.M., Li, L.S., Liu, Z.H., Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. Br. J. Pharmacol. 153 (2008), 1456–1464.
243. Ziyadeh, F.N., Hoffman, B.B., Han, D.C., Iglesias-De La Cruz, M.C., Hong, S.W., Isono, M., Chen, S., McGowan, T.A., Sharma, K., Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U S A 97 (2000), 8015–8020.
244. Zoncu, R., Efeyan, A., Sabatini, D.M., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12 (2011), 21–35.
245. Zou, L., Wang, W., Xu, Z., Zhang, N., Jiang, T., Aldose reductase regulates platelet-derived growth factor-induced proliferation through mediating cell cycle progression in rat mesangial cells. Int J. Mol. Med. 30 (2012), 409–416.